Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

KZIA Relative to the S&P 500

KZIA Relative to the Sector

Seasonal Chart Analysis

Analysis of the Kazia Therapeutics Ltd. (NASD:KZIA) seasonal charts above shows that a Buy Date of December 25 and a Sell Date of April 9 has resulted in a geometric average return of 12.77% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a fair rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 49.67% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing?anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

To download KZIA seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: KZIA